Patients with active intravascular clotting because of the risk of thrombosis. Patients with a predisposition to thrombosis are also at risk if given antifibrinolytic therapy. Hemorrhage due to disseminated intravascular coagulation should, therefore, not be treated with antifibrinolytic compounds unless the condition is predominantly due to disturbances in fibrinolytic mechanisms; tranexamic acid has been used when the latter conditions are met but with monitoring and anticoagulant cover.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
